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[18F]FDG-6-P as a novel in vivo tool for imaging
staphylococcal infections
Bethany Mills1, Ramla O Awais2, Jeni Luckett1,2, Dave Turton3, Paul Williams1, Alan C Perkins2 and Philip J Hill4*
Abstract
Background: Management of infection is a major clinical problem. Staphylococcus aureus is a Gram-positive
bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can
be life-threatening and are frequently complicated by multi-antibiotic resistant strains including methicillin-resistant
S. aureus (MRSA). Fluorodeoxyglucose ([18F]FDG) imaging has been used to identify infection sites; however, it is unable
to distinguish between sterile inflammation and bacterial load. We have modified [18F]FDG by phosphorylation,
producing [18F]FDG-6-P to facilitate specific uptake and accumulation by S. aureus through hexose phosphate
transporters, which are not present in mammalian cell membranes. This approach leads to the specific uptake of
the radiopharmaceutical into the bacteria and not the sites of sterile inflammation.
Methods: [18F]FDG-6-P was synthesised from [18F]FDG. Yield, purity and stability were confirmed by RP-HPLC and
iTLC. The specificity of [18F]FDG-6-P for the bacterial universal hexose phosphate transporter (UHPT) was confirmed
with S. aureus and mammalian cell assays in vitro. Whole body biodistribution and accumulation of [18F]FDG-6-P at
the sites of bioluminescent staphylococcal infection were established in a murine foreign body infection model.
Results: In vitro validation assays demonstrated that [18F]FDG-6-P was stable and specifically transported into S.
aureus but not mammalian cells. [18F]FDG-6-P was elevated at the sites of S. aureus infection in vivo compared to
uninfected controls; however, the increase in signal was not significant and unexpectedly, the whole-body
biodistribution of [18F]FDG-6-P was similar to that of [18F]FDG.
Conclusions: Despite conclusive in vitro validation, [18F]FDG-6-P did not behave as predicted in vivo. However at
the site of known infection, [18F]FDG-6-P levels were elevated compared with uninfected controls, providing a
higher signal-to-noise ratio. The bacterial UHPT can transport hexose phosphates other than glucose, and therefore
alternative sugars may show differential biodistribution and provide a means for specific bacterial detection.
Keywords: Pre-clinical; NanoPET-CT imaging; S. aureus; Infection diagnosis
Background
Nuclear imaging provides a platform for identifying sites
of bacterial infection in the clinic more rapidly than
traditional diagnostic microbiology laboratory methods
allow. However, the clinical imaging agents currently
employed for this purpose (such as radiolabelled leuko-
cytes [1-4] or [18F]FDG (2-fluoro-2-deoxy-D-glucose)
[5-9]) are non-specific and as such may accumulate at
sites of sterile inflammation or other lesions, resulting
in a high rate of false positive results [9-15]. Despite
concerted efforts over the past decade to develop
bacteria-specific probes for direct nuclear imaging of in-
fection, [18F]FDG remains the primary radiopharmaceu-
tical for positron emission tomography (PET) imaging
[5-9]; however, a number of other radiopharmaceuticals
are currently under pre-clinical development [16,17].
Selective uptake into bacteria in in vivo experimental
murine infection models exploits the ability of bacterial
cells to internalise alternative sugars to mammalian
cells. This offers a strategy that could be exploited for
imaging bacterial infection sites independent of host
inflammatory responses.
Staphylococcus aureus colonises 30% of the adult popu-
lation at any one time, and hospital-acquired methicillin-
resistant S. aureus (MRSA) strains (HA-MRSA) are the
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most common multi-drug resistant (MDR) bacteria iso-
lated from European hospitals [18-21]. It causes a wide
range of infections including skin and soft tissue (such as
impetigo or abscesses), deep bone and foreign body infec-
tions that can lead to sepsis and pneumonia [22]. The high
rate of MDR bacterial infections has, in large part, been
exacerbated by misdiagnosis, and therefore inappropriate
treatment [20,21,23,24]. Moreover, community-acquired
MRSA (CA-MRSA) infections are growing in prevalence,
causing disease in otherwise healthy individuals [25-29].
Therefore, developing new radiopharmaceuticals that
enable rapid diagnosis of staphylococcal infections is
imperative.
To this end, we have exploited an alternative sugar
transporter, the bacterial universal hexose phosphate
transporter (UHPT) [30]. The UHPT is expressed by
many different Gram-positive and Gram-negative bacter-
ial species including S. aureus and is induced by extra-
cellular glucose-6-phosphate. It is the sole mechanism
by which sugar phosphates are internalised into the
staphylococcal cell. Consequently, this defined route for
staphylococcal transport of glucose-6-phosphate makes
UHPT an ideal candidate for the delivery of targeted
bacteria-specific probes. [18F]FDG and [18F]FDG-6-P are
analogues of glucose, and it is reasonable to assume that
[18F]FDG-6-P would be selectively transported into
bacterial cells, which, in contrast to mammalian cells,
can internalise sugar phosphates from their surround-
ing environment. This would lead to high signal-to-
background ratio and enables specific diagnosis of
infection, rather than sterile inflammation. Here we report
on the evaluation of [18F]FDG-6-P as an imaging agent for
S. aureus infection in vivo using pre-clinical PET-CT.
Methods
Ethics statement
All animal experiments were approved by the University
of Nottingham Animal Welfare and Ethical Review
Board and performed in accordance with the UK Home
Office Licence rules, under Project Licence 40/3821. All
injected volumes were in line with ASPA guidelines.
Statistical analysis
Statistical analysis was performed using Prism 6 (GraphPad
Software Inc., La Jolla, CA, USA). Where appropriate,
analyses were performed by student's t-test (for in vitro
analysis) and Mann-Whitney U test (for in vivo analysis).
Unless otherwise stated, for in vitro data, error bars show
standard error of the mean (SEM); for in vivo data, bars
on graphs show data median.
Synthesis and analysis of [18F]FDG-6-P
[18F]FDG-6-P was prepared from commercially available
[18F]FDG (PETNET Solutions, Nottingham, UK) following
a method previously described [31]. The purity of the
[18F]FDG-6-P product was determined by reverse-phase
high-performance liquid chromatography (RP-HPLC) on
an Agilent 1260 Series LC (Agilent Technologies, Sta.
Clara, CA, USA) connected to Flow-RAM™ sodium iodide
detector (LabLogic Systems Limited, Sheffield, UK). A
SphereClone SAX 5 μm 250 × 4.6 mm column (Phenom-
enex, Torrance, CA, USA) was used for RP-HPLC at a
flow rate of 0.8 ml min−1 with UV detection at 295 nm,
using an isocratic method with 20 mmol l−1 potassium
phosphate (pH 7.2) as the mobile phase. Instant thin layer
chromatography (iTLC) was carried out using reverse-
phase plates (Merck F254 aluminium sheet silica plates,
1.0 × 7.0 cm; Merck & Co., Whitehouse Station, NJ, USA).
Radiolabelling efficiency on iTLC strips was measured
using a Bioscan radio-TLC Scanner (LabLogic, Sheffield,
UK). To ensure the stability of [18F]FDG-6-P over time,
2 MBq of [18F]FDG-6-P was incubated at 37°C for up to
3 h in 1 ml water or for 1 h in 1 ml blood (extracted from
mice and heparinised). The products were analysed by
HPLC (water) or iTLC (blood).
[18F]FDG-6-P uptake assays
S. aureus RN6390 and a UHPT-deficient strain S. aureus
RN6390 ΔuhpT were grown overnight in tryptic soy
broth (TSB, Oxoid Microbiology Products; Thermo
Fisher Scientific, Basingstoke, Hampshire, UK) at 37°C,
with shaking at 250 rpm. The overnight cultures were
diluted to OD600 0.1 and incubated until mid-exponential
phase was reached. One millilitre of cells was harvested
(1 × 108 CFU), washed and resuspended in 1 ml RPMI
1640 (Life Technologies, Carlsbad, CA, USA).
Jurkat, AGS, THP1 and HL60 cell lines were grown in
RPMI 1640 tissue culture medium supplemented with
L-glutamine, 10% v/v foetal calf serum (FCS) and 1% w/v
penicillin/streptomycin (P/S). The cells were grown in 75-
cm2 flasks at 37°C and 5% CO2. The cells were maintained
at 0.5 to 1 × 106 cells ml−1. HL60 cells were supplemented
with 1.3% v/v DMSO for 3 to 4 days followed by 24 h
without DMSO prior to experimentation in order to in-
crease expression of CD11b. AGS cells were seeded into
6-well plates (Corning Inc., Corning, NY, USA) prior to
experimentation.
HIB-1B and 3 T3-L1 cell lines were grown in DMEM
(Gibco; Life Technologies) tissue culture medium,
supplemented with 10% v/v FCS, 1% w/v P/S and 1% w/
v sodium pyruvate. The cells were grown in 75 cm2
flasks at 37°C and 5% CO2. The cells did not exceed 80%
confluence. HIB-1B cell lines were seeded into 6-well
plates and underwent differentiation by incubation with
DMEM supplemented with 10% v/v FCS, 1% P/S, 1%
sodium pyruvate, 3-isobutyl-L-methylxanthine (IBMX,
500 μM), dexamethasone (DEX, 250 nM), insulin (170
nM) and triiodo-L-thyronine (T3, 10 nM) for 48 h. The
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cells were then incubated with fresh DMEM supple-
mented with 2% v/v FCS, T3 (10 nM) and insulin (170
nM) every 48 h for 8 days. The 3 T3-L1 cells were
seeded into 6-well plates and underwent differentiation
by incubation with DMEM supplemented with 10% v/v
FCS, 1% w/v P/S, 1% w/v sodium pyruvate, IBMX
(500 μM), DEX (250 nM) and insulin (170 nM) for 48 h.
The cells were then incubated in fresh DMEM supple-
mented with 10% v/v FCS, 1% P/S, 1% w/v sodium pyru-
vate and insulin (170 nM) every 48 h for 8 days.
For experimentation, non-adherent cell lines (HL60,
THP1, Jurkat; 1 × 106 cells ml−1) were harvested, washed
and resuspended in 1 ml tissue culture medium. The
adherent cell lines (AGS, HIB-1B and 3 T3-L1) were
maintained in 6-well plates and were 80% confluent.
Each cell type (bacterial or mammalian) and controls
without cells were incubated with 2 MBq [18F]FDG or
2 MBq [18F]FDG-6-P for 1 h at 37°C. Bacteria and non-
adherent mammalian cells were harvested by centrifu-
gation (600 × g, 5 min) and washed three times by
centrifugation. All supernatants were collected for
each sample in scintillation vials. After washing, the
cells were transferred into scintillation vials. Adherent
cell lines were washed three times by replacing the well
medium. Supernatants were collected into scintillation
vials. The cells were removed from the wells by trypsin
treatment and placed into scintillation vials. The scin-
tillation vials for cells and supernatants were counted
by gamma counter (1480 Automatic Gamma Counter,
PerkinElmer Inc., Waltham, MA, USA), and the results
were obtained as counts per min (cpm).
Results were normalised for controls (no cells) and by
calculating the percentage of activity in the cell contain-
ing scintillation vials compared with the total counts
(cells and supernatant combined). The percentage of ac-
tivity associated with the cells was normalised so that
[18F]FDG cell uptake was equivalent to 1. The samples
were incubated in triplicate, and the data were presented
from at least two independent repeats.
Animal models and infection
Female BALB/c mice, 19 to 22 g (Charles River Laborator-
ies, Tranent, UK) were used for all experimentation. All
injections were performed using a 25-G insulin needle
and syringe (Becton Dickinson and Co., Franklin Lakes,
NJ, USA). Silicone 5-mm-long catheter sections (scale Fr
8, RUSCH Brilliant Pediatric, Teleflex Inc., Wayne, PA,
USA) were implanted subcutaneously (sc) into the right
flank of the mice as previously described [32,33], with the
following modifications. Analgesia (carprofen (Rimadyl),
5 mg kg−1, Pfizer Inc., New York, NY, USA) was admin-
istered by sc injection 60 min prior to anaesthesia (in-
halation of 2% isoflurane in oxygen). The incision site
was shaved and cleansed with chlorhexidine gluconate
(Hydrex Surgical Scrub) clear solution (Ecolab, Northwich,
Cheshire, UK). After insertion of the catheter, the incision
site was sealed with tissue adhesive (GLUture, Abbott
Laboratories, Maidenhead, UK). The incision sites were
healed for at least 7 days prior to inoculation with bacteria.
The bioluminescent (BL) S. aureus strain Xen29 (1 ×
107 CFU) in 50 μl saline (n = 6) or saline only (n = 5) was
administered directly into the catheter lumen. Mice were
imaged optically using an IVIS Spectrum (PerkinElmer)
to confirm the presence of BL bacteria. The images were
captured for 30 s with small (4 × 4) binning. Optical data
was processed with Living Image 3.2 software (Caliper
Life Sciences, Hopkinton, MA, USA). All mice were
maintained under anaesthesia by inhalation of 2% v/v
isoflurane in oxygen for the duration of imaging (optical
or nuclear).
NanoScan PET-CT imaging
At 24 h post bacterial inoculation, mice were injected
with 10 MBq [18F]FDG (n = 3 infected, n = 3 uninfected)
or [18F]FDG-6-P (n = 3 infected, n = 2 uninfected) by in-
traperitoneal (ip) injection. All scans were carried out
1 h later using a nanoScan PET-CT (Mediso Medical
Imaging Systems, Budapest, Hungary) small animal scan-
ner with the following parameters: CT: 1 field of view
(FOV), maximum FOV, full scan, 720 projections; tube
35 kVP, 170 ms exposure, 1:1 binning. PET: coinci-
dence 1:5, scan time 20 min, packet timestamp. Scan-
ning and subsequent reconstruction were carried out
using Nucline software (Mediso). Reconstruction pa-
rameters are as follows: 3D, whole body, non-dynamic
with 1:3 binning.
NanoScan PET-CT data analysis
All image analysis was performed with VivoQuant soft-
ware (inviCRO LLC, Boston, MA, USA). All data were
normalised for min/max counts based on exact radio-
pharmaceutical injection dose; radiopharmaceutical sig-
nal from bladders was masked and all images were
scaled equally. 3D regions of interest (ROIs) were drawn
manually or using integrated thresholding tools (global)
where appropriate. Standardised uptake values (SUVs)
were calculated for each ROI using the following for-
mula: ROI concentration (MBq mm−3)/(Injected dose
(MBq)/Mouse weight (kg)). To determine the infected to
uninfected (I/UI) ratio of infected vs. uninfected cathe-
ters, the mean SUV for the infected mouse catheter was
divided by the mean catheter SUV of the uninfected
mouse.
Results
Synthesis and stability of [18F]FDG-6-P
[18F]FDG-6-P was synthesised from [18F]FDG as previ-
ously described [31]. The [18F]FDG-6-P product was
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analysed by iTLC (Figure 1a) and RP-HPLC (Figure 1b)
in order to confirm yield and determine that the [18F]
FDG-6-P peak could be distinguished from that of
[18F]FDG by both methods. Analysis by HPLC deter-
mined that the retention time of [18F]FDG-6-P was
approximately 8 min and that of [18F]FDG was
approximately 3 min. The retention factors (Rf ) of
[18F]FDG-6-P and [18F]FDG measured by iTLC were
0.27 and 0.41 respectively. The stability of [18F]FDG-6-
P over time was confirmed by HPLC analysis after
incubation of the radiopharmaceutical in water for 3 h
(Figure 1b).
Figure 1 Determination of the purity of [18F]FDG-6-P. By (a) iTLC at 0 h and (b) RP-HPLC after incubation of the radiopharmaceutical in water
for 3 h. The retention profiles of [18F]FDG-6-P were easily resolved from that of [18F]FDG, the most likely breakdown product of [18F]FDG-6-P. No
changes in the [18F]FDG-6-P peak or retention time were observed.
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UHPT is required for [18F]FDG-6-P uptake
Despite [18F]FDG-6-P being a homologue of glucose-6-
phosphate, it was not known whether this radiopharma-
ceutical would be transported by the staphylococcal
UHPT. S. aureus RN6390 and UHPT-deficient S. aureus
RN6390 ΔuhpT were incubated with 2 MBq of [18F]FDG
or [18F]FDG-6-P. After incubation, the relative activity of
each radiopharmaceutical associated with the bacterial
cells was calculated (Figure 2a).
The S. aureus RN6390 parent and S. aureus RN6390
ΔuhpT mutant strains demonstrated comparable uptake
of [18F]FDG. However, only S. aureus RN6390 was able
to transport and accumulate [18F]FDG-6-P, indicating
that [18F]FDG-6-P was a specific substrate for the UHPT.
In addition, the amount of [18F]FDG-6-P activity associ-
ated with the parent strain was significantly elevated com-
pared with [18F]FDG (P = 0.0015).
In order for [18F]FDG-6-P to be a potential transla-
tional tool for the specific diagnosis of bacterial infec-
tions, it should not be transported into mammalian
cells. Consequently, several mammalian cell lines of
both human (HL60, Jurkat, AGS and THP1) and mur-
ine origins (HIB-1B and 3 T3-L1) were incubated with
[18F]FDG or [18F]FDG-6-P, and the relative activity
associated with the cells was determined (Figure 2b).
For each cell line, significantly more [18F]FDG was
associated with the cells than [18F]FDG-6-P (HL60
P = 0.0066; Jurkat P = 0.0089; AGS P = 0.0218; THP1
P = 0.0002; HIB-1B P = 0.0004; 3 T3-L1 P < 0.0001).
The relative amount of [18F]FDG-6-P uptake in the
mammalian cell lines was comparable with that of the
UHPT-deficient staphylococcal mutant, indicating there
was no specific mammalian cell transport system for the
phosphorylated sugar.
Figure 2 Uptake of [18F]FDG-6-P and [18F]FDG by S. aureus and mammalian cells. (a) S. aureus RN6390 and the isogenic UHPT-deficient
mutant were incubated with either [18F]FDG or [18F]FDG-6-P. The activity associated with each of the strains after incubation with [18F]FDG (black)
or [18F]FDG-6-P (white) was measured using a gamma counter. Counts were normalised to remove ‘no cell’ control counts and to compare [18F]
FDG-6-P uptake with [18F]FDG uptake. Error bars show SEM. **P = 0.0015; ****P < 0.0001. Data were collected from three independent repeats. (b)
The activity associated with mammalian cell lines HL60, Jurkat, AGS, THP1, HIB-1B and 3 T3-L1 after incubation with [18F]FDG (black) or [18F]FDG-6-P
(white) was measured using a gamma counter. The counts were normalised to compare [18F]FDG-6-P uptake with [18F]FDG uptake. Error bars show
SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Differences in the means of cells incubated with [18F]FDG-6-P were not significant.
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Biodistribution of [18F]FDG-6-P was similar to [18F]FDG
Infections were confirmed by BL imaging of all mice
(Figure 3a). Whole body nanoScan PET-CT imaging of
mice with implanted catheters (infected and uninfected)
1 h post injection of approximately 10 MBq [18F]FDG-6-
P was performed (administered doses ranged between 8
and 11 MBq). The biodistribution of [18F]FDG-6-P was
shown to be visually comparable with that of [18F]FDG,
which had been similarly administered by ip injection
into a secondary cohort of mice (administered doses
ranged between 8 and 11 MBq). No uptake of [18F]FDG-
6-P into host tissues was anticipated; however, as for the
[18F]FDG biodistribution, [18F]FDG-6-P activity was cap-
tured from the leg muscles, heart, brown adipose tissue
(BAT) and brain (Figure 3b), as well as the infected cath-
eter (Figure 3b, yellow arrows). The biodistribution of
[18F]FDG and [18F]FDG-6-P was further quantified by
calculating SUVs for the following organs: BAT, heart,
brain, right thigh and left thigh. These were calculated
for S. aureus-infected mice (Figure 3c, [18F]FDG n = 3
and [18F]FDG-6-P n = 3) and uninfected mice (Figure 3d,
[18F]FDG n = 3 and [18F]FDG-6-P n = 2). The SUV
values for specific organs varied per mouse; however, the
trend demonstrated that infection did not greatly affect
the whole-body biodistribution of either of the radio-
pharmaceuticals and that [18F]FDG-6-P biodistribution
was not significantly different to that of [18F]FDG.
[18F]FDG-6-P was not dephosphorylated in the blood
The in vivo biodistribution of [18F]FDG-6-P was highly
unexpected. In order to explore whether the [18F]FDG-6-P
was being dephosphorylated to produce [18F]FDG during
Figure 3 In vivo biodistribution of [18F]FDG-6-P and [18F]FDG. (a) Representative optical image confirming the presence of BL catheter-associated
S. aureus on the day of the nanoScan PET-CT scan. (b) Whole body biodistributions from nanoPET-CT scans of mice with sc implanted catheters
inoculated with or without S. aureus 1 h after ip injection of approximately 10 MBq [18F]FDG or [18F]FDG-6-P; catheters are shown with arrows.
SUVs were calculated from 3D ROIs drawn for each mouse from the whole-body nanoScan PET-CT images for (c) infected ([18F]FDG n = 3; [18F]
FDG-6-P n = 3) and (d) uninfected mice ([18F]FDG n = 3; [18F]FDG-6-P n = 2. Black circle, [18F]FDG; black square, [18F]FDG-6-P). Bars on graph
show median. BAT, brown adipose tissue.
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systemic circulation, samples of mouse blood were
collected and incubated with either [18F]FDG or [18F]
FDG-6-P ex vivo for 1 h. The blood was analysed by
iTLC to examine the peak profiles for each of the
radiopharmaceuticals (Figure 4). As anticipated, the
blood incubated with [18F]FDG showed two defined
peaks; a large peak consistent with intracellular [18F]
FDG-6-P (which arises from phosphorylation of [18F]
FDG as it passes through glucose transporters into the
cell) and a smaller [18F]FDG peak (indicating that
some [18F]FDG had not yet been transported into the
cells). The blood incubated with [18F]FDG-6-P had
only one defined peak, consistent with the [18F]FDG-6-
P standard which had not been incubated with blood,
indicating that [18F]FDG-6-P was not being dephos-
phorylated to [18F]FDG.
[18F]FDG-6-P provides a higher signal-to-noise ratio than
[18F]FDG at the infection site
Despite the unexpected whole-body biodistribution of
[18F]FDG-6-P in vivo, the accumulation of [18F]FDG-6-P
and [18F]FDG at the site of bacterial catheter foreign
body infections was characterised. After image recon-
struction of data captured from the nanoScan PET-CT
scans (Figure 3b), the catheter regions were cropped
from the whole body image and scales normalised based
on injected activity in order to visualise activity associ-
ated with the catheter (Figure 5a). Visually, [18F]FDG
was present at the site of both infected and uninfected
catheters and as expected, [18F]FDG accumulated to a
higher concentration when bacteria were present. The
activity present at either end of the uninfected catheter
could indicate inflammation at these positions where the
rough, cut surface of the catheter was in contact with
the tissue. For the infected mice, it was apparent that
the majority of the activity was associated on the outside
of the catheter and the surrounding tissue, rather than
inside the lumen of the catheter where a large bacterial
population was expected. These data suggest that the
radiopharmaceutical may not be reaching the majority of
bacterial cells.
A similar accumulation pattern was observed for in-
fected mice injected with [18F]FDG-6-P (Figure 5a).
However, differences in accumulation between the two
radiopharmaceuticals were visualised at the catheter
site of uninfected mice. Unlike [18F]FDG, [18F]FDG-6-
P did not accumulate at the sites of sterile inflamma-
tion at the ends of the catheter, suggesting that [18F]
FDG-6-P was not accumulating within the inflamma-
tory cells.
The accumulation of [18F]FDG and [18F]FDG-6-P at
the site of the catheter was further quantified by calcu-
lating the SUV of the activity around each of the cathe-
ters. The SUVs demonstrated that [18F]FDG was a poor
tool for identifying bacterial infection due to high back-
ground signal in uninfected controls (Figure 5b); the
trend in accumulation was only marginally increased for
infected vs. uninfected mice. The SUVs for [18F]FDG-6-
P injected mice (Figure 5b) demonstrated a lower back-
ground signal in uninfected mice compared to infected
mice and compared with [18F]FDG control mice. How-
ever, the decrease was not significant.
Infected to uninfected (I/UI) ratios were calculated for
the catheter site based on the mean SUV value for each
group (Figure 5c). For each graph, a value of 1 would
show equal SUVs for infected and uninfected mice. The
I/UI ratio for [18F]FDG-6-P infected mice was more than
double that of the [18F]FDG injected cohort, indicat-
ing a clear difference in accumulation of the radio-
pharmaceuticals at the sites of infection compared
with inflammation.
Figure 4 Stability of [18F]FDG-6-P in the blood. Blood extracted
from mice was incubated with [18F]FDG or [18F]FDG-6-P for 1 h. The
blood was analysed by iTLC to determine whether any additional
peaks indicating dephosphorylation of [18F]FDG-6-P. The dotted line
shows the peak for the [18F]FDG-6-P standard, and the dashed line
shows the peak for the [18F]FDG standards which were not
incubated with blood.
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Discussion
The aim of this study was to address the ever-increasing
need for better, bacteria-specific diagnostic radiopharma-
ceuticals for translation into the clinical setting. Here we
have exploited an alternative sugar transporter unique to
and highly conserved in several bacteria, thereby negat-
ing the current issues with targeting host inflammatory
cells and the high non-specific background currently ob-
served with [18F]FDG imaging. During the preparation
of this manuscript, Gowrishankar [34] and Weinstein
[35] reported the exploitation of bacteria-specific sugar
transporters for maltose and sorbitol using 6-[18 F]-fluor-
omaltose [34] and [18F]-fluorodeoxysorbitol ([18F]FDS)
respectively for pre-clinical imaging. [18F]FDS can be
prepared from [18F]FDG, the most widely available PET
imaging radiopharmaceutical and therefore [18F]FDS
could potentially be used in any clinic with access to
[18F]FDG. However, [18F]FDS is specific for the Gram-
Figure 5 Accumulation of [18F]FDG and [18F]FDG-6-P at the catheter infection site. Mice with S. aureus infections (or uninfected control
mice) were injected with approximately 10 MBq [18F]FDG (n = 3 infected, n = 3 uninfected) or approximately 10 MBq [18F]FDG-6-P (n = 3 infected,
n = 2 uninfected) 1 h prior to nanoScan PET-CT imaging. (a) Representative 3D colour map of catheter regions cropped from whole-body
nanoScan PET-CT images. Images are shown with and without CT. (b) SUV values were calculated for S. aureus-infected (black circle) and
uninfected mice (black square). Mann-Whitney U tests confirmed that there were no significant differences in SUVs between infected and uninfected
mice injected with either [18F]FDG (P = 0.7619) or [18F]FDG-6-P (P = 0.0556). Bars on the graph show median SUVs for each group (n = 3 for [18F]FDG
infected and n = 3 for uninfected mice; n = 3 for [18F]FDG-6-P infected mice and n = 2 uninfected mice). (c) The infected (I) to uninfected (UI) ratio
(I/UI) for the catheter sites of mice injected with [18F]FDG and [18F]FDG-6-P was calculated by dividing the mean infected catheter SUV by the mean
uninfected catheter SUV for each cohort of mice.
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negative Enterobacteriaceae and so cannot be used for
imaging S. aureus infections. The development of an
imaging agent to detect S. aureus infections is therefore
urgently required. As stated within the introduction,
MRSA strains are the most widely isolated multi-
antibiotic resistant bacteria found within European
hospitals [20,21]. Moreover, S. aureus is particularly
problematic and difficult to eradicate because of its
ability to cause chronic infections through biofilm forma-
tion on indwelling medical devices such as catheters,
pacemakers and prosthetic joints [36,37]. Furthermore,
due to the expanding ageing population, there is an ever-
increasing demand for such devices, placing more patients
at risk of contacting staphylococcal infections [38].
To create a radiopharmaceutical with translatable
potential for specifically identifying bacterial infections,
including those caused by S. aureus, the UHPT was se-
lected as a target [30]. The UHPT is conserved amongst
several bacterial strains, including Staphylococcus,
Escherichia, Shigella and Enterobacter, and is able to
transport a number of hexose-6-phosphate sugars. The
UHPT transporter is highly expressed by S. aureus and
due to clinical demand for tools to diagnose this patho-
gen, it was selected for use in this study.
Due to its accepted clinical use and widespread avail-
ability, we chose to modify [18F]FDG by converting it to
the corresponding phosphate analogue, [18F]FDG-6-P.
The latter was confirmed as a substrate for the bacterial
UHPT in in vitro accumulation assays in comparison
with [18F]FDG. S. aureus RN6390 and the isogenic
UHPT mutant strain accumulated [18F]FDG to the same
extent, although the level of [18F]FDG-6-P in the paren-
tal cells was significantly higher. This was consistent
with the elevated growth rates observed when S. aureus
RN6390 was supplemented with glucose-6-phosphate in-
stead of glucose (data not shown), suggesting that the
UHPT was active and could allow even higher levels of
[18F]FDG-6-P to accumulate at the site of infection com-
pared with [18F]FDG, resulting in an elevated signal-to
background ratio. Accumulation assays with [18F]FDG
and [18F]FDG-6-P and various mammalian cell lines
in vitro were performed to confirm that eukaryotic cells
did not transport [18F]FDG-6-P. It is important to note
that both murine and human-derived cell lines were
used for the in vitro assays and no differences in radio-
pharmaceutical accumulation were observed. Therefore,
it was anticipated that [18F]FDG-6-P biodistribution and
accumulation in both mice and humans would be
similar.
Pre-clinical in vivo infection studies with [18F]FDG-6-
P were therefore performed. A foreign body model of
infection with S. aureus was used to replicate clinical sit-
uations where biofilm formation results in chronic infec-
tions that are refractory to antibiotic therapy [36,39,40].
For these studies, the mice were not fasted, warmed or
maintained under anaesthetics between radiopharma-
ceutical administration and imaging as is suggested for
optimal [18F]FDG imaging [41,42] because it was antici-
pated that non-specific background from [18F]FDG-6-P
after clearance from the blood pool would be minimal.
Mice injected with [18F]FDG were prepared identically
to those injected with [18F]FDG-6-P to enable direct
comparisons. All mice were imaged optically to confirm
equivalent infection levels prior to [18F]FDG-6-P or [18F]
FDG administration.
Unexpectedly, very high levels of background signal
from mice injected with [18F]FDG-6-P were observed for
both infected and uninfected mice. The whole-body bio-
distribution of [18F]FDG and [18F]FDG-6-P was visually
similar, and this was confirmed when SUVs were calcu-
lated from ROIs of the brown adipose tissue, heart, brain
and right and left thighs. The first potential explanation
for this finding was that the [18F]FDG-6-P was either
unstable or was specifically dephosphorylated within the
systemic circulation in the mouse, resulting in the re-
lease of free [18F]FDG which could then be transported
into mammalian cells by GLUT transporters. However,
glucose-6-phosphatase distribution in mice has previ-
ously been studied with ex vivo whole-body autoradiog-
raphy [43]. This study revealed that high levels of the
enzyme were present in the liver, kidney, intestine and
skeletal system, but not in the circulatory system. The
stability of [18F]FDG-6-P in the blood was also con-
firmed by ex vivo incubation and analysis by iTLC.
Despite the accepted understanding that mammalian
cells do not transport phosphorylated sugars, there have
been few reports in the literature. To our knowledge,
there is only one published study investigating glucose-
6-phosphate uptake in mammalian cell lines [44]. How-
ever, the authors speculated that the apparent growth of
the cells incubated with glucose-6-phosphate may be a
result of proteins in their tissue culture medium dephos-
phorylating the glucose-6-phosphate, releasing glucose
for transport and subsequent metabolism. Unfortunately,
no further studies to determine whether mammals are
able to transport phosphorylated sugars have been
reported.
Critically, despite the similarity in the whole-body bio-
distribution of [18F]FDG-6-P and [18F]FDG, differences
between the two radiopharmaceuticals were observed at
the site of the catheter implant for uninfected mice.
[18F]FDG but not [18F]FDG-6-P accumulated at the ends
of the catheters which are likely to be sites of sterile
inflammation. It can be assumed that similar levels of
inflammation were present at the ends of the catheters
as all catheters were prepared and implanted in the same
way. This suggests that the two radiopharmaceuticals be-
have differently and that [18F]FDG-6-P was not present
Mills et al. EJNMMI Research  (2015) 5:13 Page 9 of 11
as [18F]FDG. This raises the prospect that the observed
uptake of [18F]FDG-6-P into the other organs may be a
real process and so warrants further investigation to
determine whether this phenomenon extends to man.
Importantly, the reduced [18F]FDG-6-P activity at the
catheter site of uninfected mice in this proof of concept
study demonstrated that the [18F]FDG-6-P activity around
the infected catheter is associated specifically with S. aur-
eus and not inflammatory cells; however, due to the small
sample size, it is not possible to determine statistical
significance.
Conclusions
Based on our in vivo studies, it is clear that [18F]FDG-6-
P did not behave as expected within the mouse model;
however, the radioactivity at the infection site was ele-
vated more than twofold for infected mice compared
with uninfected controls injected with [18F]FDG-6-P and
compared with [18F]FDG. This indicated that [18F]FDG-
6-P did not accumulate within the inflammatory cells
and so this could conceivably provide a means to distin-
guish between sites of sterile inflammation and S. aureus
infection, an important limitation of [18F]FDG imaging
[45]. In addition, the UHPT is also able to transport
other hexose phosphates, such as mannose-6-phosphate
and fructose-6-phosphate (data not shown). We propose
therefore that fluorinating these sugars with [18F] may
enable the specific targeting of the UHPT, reducing
background uptake and provide a more favourable bio-
distribution for in vivo imaging.
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